---
pmid: '28257760'
title: Induction of MiR133a expression by IL-19 targets LDLRAP1 and reduces oxLDL
  uptake in VSMC.
authors:
- Gabunia K
- Herman AB
- Ray M
- Kelemen SE
- England RN
- DeLa Cadena R
- Foster WJ
- Elliott KJ
- Eguchi S
- Autieri MV
journal: J Mol Cell Cardiol
year: '2017'
full_text_available: false
pmcid: PMC5394383
doi: 10.1016/j.yjmcc.2017.02.005
---

# Induction of MiR133a expression by IL-19 targets LDLRAP1 and reduces oxLDL uptake in VSMC.
**Authors:** Gabunia K, Herman AB, Ray M, Kelemen SE, England RN, DeLa Cadena R, Foster WJ, Elliott KJ, Eguchi S, Autieri MV
**Journal:** J Mol Cell Cardiol (2017)
**DOI:** [10.1016/j.yjmcc.2017.02.005](https://doi.org/10.1016/j.yjmcc.2017.02.005)
**PMC:** [PMC5394383](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394383/)

## Abstract

1. J Mol Cell Cardiol. 2017 Apr;105:38-48. doi: 10.1016/j.yjmcc.2017.02.005. Epub
 2017 Feb 28.

Induction of MiR133a expression by IL-19 targets LDLRAP1 and reduces oxLDL 
uptake in VSMC.

Gabunia K(1), Herman AB(1), Ray M(1), Kelemen SE(1), England RN(1), DeLa Cadena 
R(1), Foster WJ(2), Elliott KJ(1), Eguchi S(1), Autieri MV(3).

Author information:
(1)Department of Physiology, Independence Blue Cross Cardiovascular Research 
Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 
19140, United States.
(2)Departments of Ophthalmology & Bioengineering, Independence Blue Cross 
Cardiovascular Research Center, Lewis Katz School of Medicine at Temple 
University, Philadelphia, PA 19140, United States.
(3)Department of Physiology, Independence Blue Cross Cardiovascular Research 
Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 
19140, United States. Electronic address: mautieri@temple.edu.

The transformation of vascular smooth muscle cells [VSMC] into foam cells 
leading to increased plaque size and decreased stability is a key, yet 
understudied step in atherogenesis. We reported that Interleukin-19 (IL-19), a 
novel, anti-inflammatory cytokine, attenuates atherosclerosis by 
anti-inflammatory effects on VSMC. In this work we report that IL-19 induces 
expression of miR133a, a muscle-specific miRNA, in VSMC. Although previously 
unreported, we report that miR133a can target and reduce mRNA abundance, mRNA 
stability, and protein expression of Low Density Lipoprotein Receptor Adaptor 
Protein 1, (LDLRAP1), an adaptor protein which functions to internalize the LDL 
receptor. Mutations in this gene lead to LDL receptor malfunction and cause the 
Autosomal Recessive Hypercholesterolemia (ARH) disorder in humans. Herein we 
show that IL-19 reduces lipid accumulation in VSMC, and LDLRAP1 expression and 
oxLDL uptake in a miR133a-dependent mechanism. We show that LDLRAP1 is expressed 
in plaque and neointimal VSMC of mouse and human injured arteries. Transfection 
of miR133a and LDLRAP1 siRNA into VSMC reduces their proliferation and uptake of 
oxLDL. miR133a is significantly increased in plasma from hyperlipidemic compared 
with normolipidemic patients. Expression of miR133a in IL-19 stimulated VSMC 
represents a previously unrecognized link between vascular lipid metabolism and 
inflammation, and may represent a therapeutic opportunity to combat vascular 
inflammatory diseases.

Copyright Â© 2017 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.yjmcc.2017.02.005
PMCID: PMC5394383
PMID: 28257760 [Indexed for MEDLINE]

Conflict of interest statement: Disclosures: The authors declare no actual or 
potential conflict of interest including any financial, personal or other 
relationships with other people or organizations.
